Amkor Technology
AMKR
$32.82
+7.64%
Amkor Technology is one of the world's largest outsourced semiconductor assembly and test (OSAT) providers, packaging and testing integrated circuits for semiconductor companies, foundries, and electronics OEMs, with the bulk of revenue coming from advanced packaging technologies such as flip chip, wafer-level processing, and advanced system-in-package (SiP) modules. As a pure-play OSAT, Amkor occupies a critical but capital-intensive niche in the semiconductor supply chain, positioning it as a strategic manufacturing partner rather than a chip designer, and it competes directly with larger foundry-backed rivals like TSMC and Intel while deriving most revenue from foreign operations. The investor narrative has swung violently: enthusiasm over AI and high-performance-computing (HPC) packaging demand and a strategic TSMC partnership drove the stock to record highs in mid-2026, but a subsequent collapse in the share price — punctuated by a roughly 25% single-day drop in late July and continued erosion into November — has reframed the debate around demand durability, margin sustainability, and whether the AI packaging growth story is being priced out amid competitive pressure and heavy capital spending.…
AMKR
Amkor Technology
$32.82
Related headlines
Investment Opinion: Should I buy AMKR Today?
Rating: Hold, with a speculative accumulation bias only for risk-tolerant investors. The core thesis is that Amkor's 10.98x forward PE and 1.45x PS price in a severe AI-packaging de-rating while sequential margins expand (gross margin 14.19% to 18.26% across 2026) and every analyst target sits above the $30.49 price (average $66.00, low $41.00), but flat 0.18% YoY revenue and negative Q3 free cash flow of -$61.6 million mean the growth thesis is unproven and the falling knife is still in motion. The consensus 'buy' rating (1.91 mean across 10 analysts, 7 Buy / 4 Hold / 0 Sell) anchors a constructive but not urgent view, and the +116.5% implied upside to the average target is too wide to trust until estimates are refreshed.
Supporting evidence is genuinely two-sided. On valuation, the forward PE of 10.98x is less than half the trailing 26.15x, PS of 1.45x has collapsed from 6.53x at Q3 reporting and 11.25x in Q2 2026, price-to-book of 2.18x sits near the low end of its 1.1x-4.6x band, and EV/EBITDA of 8.56x is modest for a capital-intensive manufacturer. On fundamentals, Q3 2026 net income of $190.6 million more than doubled from $83.5 million in Q1, operating margin rose from 5.95% to 11.29%, and the balance sheet is solid with debt-to-equity of 0.35, current ratio of 2.27, and $1.80 billion of cash. Against that, revenue of $1.991 billion grew only 0.18% YoY, TTM gross margin of 13.99% and net margin of 5.57% remain structurally thin, PEG of 5.38 is elevated, and the stock's -67.41% max drawdown with beta of 2.402 shows how violently the market can reprice it.
The biggest risks that could invalidate any constructive stance are: (1) revenue failing to reaccelerate in Q4/Q1 while $548 million of quarterly capex drives depreciation of $186.6 million higher and compresses the 18.26% gross margin back toward the 14.19% Q1 level; (2) analysts cutting the stale $66.00 average target toward the $41.00 low, which would remove the last valuation anchor; and (3) competitive bundling by TSMC and Intel eroding pricing power in advanced packaging. This Hold would upgrade to Buy if revenue growth turns positive and free cash flow returns above zero while the stock holds the $29.76 low, and would downgrade to Sell on a decisive break below $29.76 with a further leg of estimate cuts. Net verdict: the stock is undervalued relative to its own history and to analyst targets, but fairly-to-fully valued relative to the currently delivered flat growth — a value trap until the top line proves the AI packaging thesis.
Sign up to view all
AMKR 12-Month Price Forecast
The forward-looking picture is a genuine tug-of-war between a valuation that has collapsed to multi-year lows (PS 1.45x, forward PE 10.98x, P/B 2.18x) and a top line that has stalled at 0.18% YoY growth despite the AI narrative that drove the stock to $96.68. The sequential margin expansion and solid balance sheet (debt-to-equity 0.35, current ratio 2.27, $1.80 billion cash) argue the operating leverage is real, but negative quarterly free cash flow shows the capex bet is not yet paying for itself and the stock's proximity to its 52-week low leaves little technical cushion. Analyst sentiment remains constructive on paper (7 Buy, 4 Hold, 0 Sell, $66.00 average target) but the +116.5% implied upside signals stale estimates rather than conviction, so the consensus should be treated with caution until refreshed. I would upgrade to bullish on evidence of positive YoY revenue growth combined with free cash flow turning positive and the stock holding above $29.76, and would downgrade to bearish on a decisive break below the 52-week low accompanied by analyst target cuts.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Amkor Technology's 12-month outlook, with a consensus price target around $66.00 and implied upside of +101.1% versus the current price.
Average Target
$66.00
11 analysts
Implied Upside
+101.1%
vs. current price
Analyst Count
11
covering this stock
Price Range
$41 - $92
Analyst target range
Amkor is covered by 10 analysts with a consensus recommendation of "buy" (mean rating of 1.91 on a 1-5 scale where lower is more bullish), comprising 7 Buy ratings, 4 Hold ratings, and 0 Sells — a moderately bullish but notably divided stance. The average price target of $66.00 implies a staggering +116.5% upside from the current $30.49, a gap so wide it signals that analyst targets have badly lagged the stock's collapse and are likely stale relative to the recent price action. The consensus leans bullish in rating but the dispersion tells a more cautious story, and the fact that the stock trades at less than half the average target suggests either a significant mispricing opportunity or that estimates are due for sharp downward revisions.
The target range is extraordinarily wide — from a low of $41.00 to a high of $92.00, a spread of more than 2.2x — which signals very high uncertainty and low conviction among analysts about Amkor's trajectory. Even the low target of $41.00 implies +34.5% upside from $30.49, meaning every published target sits above the current price, a pattern that often precedes either a sharp re-rating higher or a wave of target cuts. Recent institutional ratings show a mix of maintained positions — Needham reiterating Buy, B. Riley and Morgan Stanley maintaining Neutral/Equal Weight as of late October 2026 — with UBS notably upgrading from Neutral to Buy in late July, but no recent downgrades despite the price collapse, suggesting analysts are holding their ground pending clarity on AI packaging demand and the impact of the TSMC partnership. The wide spread and stale targets imply investors should treat consensus with caution until estimates are refreshed against the reality of the recent price action.
Drowning in data?
Find the real signal!
Bulls vs Bears: AMKR Investment Factors
The bear case currently has the stronger evidence: revenue growth of 0.18% YoY directly contradicts the AI packaging thesis that justified a $96.68 high, and the stock's 68.5% decline to within 1.1% of its 52-week low reflects a market that has lost confidence in the growth trajectory, not a temporary sentiment wobble. The bull case rests on valuation — a 10.98x forward PE, 1.45x PS at multi-year lows, and analyst targets all above $41 — but those targets look stale against a stock that fell 42.89% in a month, and negative quarterly free cash flow of -$61.6 million shows the capex bet is not yet paying for itself. The single most important tension is whether the sequential margin expansion (gross margin 14.19% to 18.26% across 2026) and the TSMC partnership translate into accelerating revenue in coming quarters; if top-line growth reaccelerates, the valuation gap closes violently, but if revenue stays flat while depreciation from $548 million of quarterly capex ramps, earnings estimates and the 10.98x forward PE both get revised lower. Until the stock stabilizes above the $29.76 low and revenue growth turns positive, the risk/reward favors patience over catching the falling knife.
Bullish
- Forward PE of 10.98x implies deep discount: The forward PE of 10.98x sits at less than half the trailing PE of 26.15x, implying the market expects earnings to roughly double. If Q3 2026's $0.77 quarterly EPS annualizes near $3.00, the stock at $30.49 trades at roughly 10x run-rate earnings — a valuation rarely seen for an AI-adjacent semiconductor supplier.
- Sequential margin expansion is real: Gross margin climbed from 14.19% in Q1 2026 to 16.79% in Q2 and 18.26% in Q3, while operating margin rose from 5.95% to 11.29% over the same span. Net income more than doubled sequentially from $83.5 million in Q1 to $190.6 million in Q3, showing operating leverage as advanced packaging volumes scale.
- Every analyst target sits above price: The lowest published target of $41.00 implies +34.5% upside from $30.49, and the $66.00 average implies +116.5%. With 7 Buy ratings, 4 Holds, and 0 Sells, and UBS upgrading to Buy in late July, no analyst has capitulated despite the collapse — a pattern that often precedes either a sharp re-rating or a wave of target cuts.
- Balance sheet provides a floor: Debt-to-equity of 0.35, a current ratio of 2.27, and $1.80 billion of cash give Amkor substantial liquidity to fund its capex build-out without distress. TTM free cash flow of $532 million remains positive despite the Q3 capex surge to $548 million, so the investment phase is funded from strength rather than leverage.
Bearish
- Revenue growth has stalled to zero: Q3 2026 revenue of $1.991 billion grew just 0.18% year-over-year versus $1.987 billion in Q3 2025, despite the AI narrative that drove the stock to $96.68. Investors priced in accelerating growth, and the flat top line is the single clearest justification for the de-rating.
- Falling knife at 52-week low: At $30.49 the stock sits just 1.1% above its 52-week low of $29.76 and 68.5% below its high, with a max drawdown of -67.41%. It fell 42.89% in the past month and 14.50% in the latest session alone, and a break below $29.76 leaves no historical support.
- Negative quarterly free cash flow: Q3 2026 free cash flow was -$61.6 million as $548 million of capex overwhelmed $487 million of operating cash flow, and the price-to-FCF ratio is -210.86. The capacity build-out is a bet on future AI demand that the market is currently refusing to underwrite.
- Extreme volatility and stock-specific selling: Beta of 2.402 makes AMKR roughly 2.4x as volatile as the S&P 500, and the 1-month relative strength versus SPY of -36.97% versus SPY's own -5.92% decline confirms this is a company-specific de-rating, not a sector pullback. The 6-month relative strength of -59.57% underscores how isolated the damage is.
AMKR Technical Analysis
Amkor is in a severe, sustained downtrend, with the stock down 16.58% over the past year and an astonishing 60.20% over six months, a decline that accelerated dramatically from its mid-year peak. At the current price of $30.49, the stock sits at just 1.1% above its 52-week low of $29.76 and a staggering 68.5% below its 52-week high of $96.68 — effectively trading at the very bottom of its 52-week range (roughly 1% of the range), a positioning that signals capitulation and falling-knife dynamics rather than a value opportunity until stabilization is confirmed. The maximum drawdown of -67.41% underscores the brutality of the reversal from what had been a powerful uptrend earlier in 2026.
Short-term momentum is unambiguously negative and deteriorating: the stock is down 42.89% over the past month and 44.83% over three months, with the most recent session alone shedding 14.50% (a $5.17 decline from the prior close of $35.66 to $30.49). This represents a clear acceleration of the downtrend rather than mere mean reversion — the 1-month decline (-42.89%) is nearly as steep as the 3-month decline (-44.83%), meaning essentially all of the three-month damage occurred in the last 30 days, a hallmark of panic selling. Relative strength confirms the underperformance is extreme and stock-specific: AMKR's 1-month relative strength versus SPY is -36.97% and its 6-month relative strength is -59.57%, far worse than the broader market's modest -5.92% one-month decline, indicating this is a company-specific de-rating rather than a sector-wide pullback.
Key technical levels are now starkly defined: support rests at the 52-week low of $29.76, just below the current $30.49, and a breakdown below that level would signal a fresh leg lower with little historical price memory to catch the fall. Resistance is layered far overhead, with the 52-week high of $96.68 representing a distant ceiling and intermediate resistance likely forming around the $40-$45 zone where the stock briefly consolidated in October. The beta of 2.402 is critical context — Amkor is roughly 2.4 times as volatile as the S&P 500, meaning position sizing must be dramatically reduced relative to a market-weight holding, and the elevated short ratio of 2.76 days-to-cover alongside a 6.9 million share volume day suggests both elevated bearish positioning and the potential for violent short-covering rallies if any positive catalyst emerges.
Beta
2.40
2.40x market volatility
Max Drawdown
-67.4%
Largest decline past year
52-Week Range
$30-$97
Price range past year
Annual Return
-6.6%
Cumulative gain past year
| Period | AMKR Return | S&P 500 |
|---|---|---|
| 1m | -37.2% | -5.0% |
| 3m | -40.6% | -4.9% |
| 6m | -57.2% | -0.5% |
| 1y | -6.6% | +9.6% |
| ytd | -23.5% | +7.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AMKR Fundamental Analysis
Amkor's revenue trajectory shows a business that is growing but decelerating sharply at the top line: Q3 2026 revenue of $1.99 billion grew just 0.18% year-over-year versus $1.987 billion in Q3 2025, a dramatic slowdown from the sequential momentum seen earlier in the year (Q1 2026: $1.685 billion; Q2 2026: $1.898 billion; Q3 2026: $1.991 billion). The sequential progression masks the YoY stagnation, and the segment mix reveals the story: Advanced Products generated $1.632 billion (roughly 82% of revenue) versus just $359 million from Mainstream Products, meaning the company's fortunes are overwhelmingly tied to the AI/HPC-driven advanced packaging cycle. The near-flat YoY growth despite the AI narrative is precisely the concern weighing on the stock — investors had priced in accelerating growth, and the actual delivery has been tepid.
Profitability is solid but margin-constrained by the OSAT business model: Q3 2026 net income was $190.6 million on a 9.58% net margin, with gross margin of 18.26% and operating margin of 11.29%, and these margins have been expanding sequentially (gross margin rose from 14.19% in Q1 to 16.79% in Q2 to 18.26% in Q3 2026). The TTM figures are less flattering — net margin of 5.57%, gross margin of 13.99%, and operating margin of 6.97% — reflecting the weaker earlier quarters, and the quarterly EPS of $0.77 (diluted $0.76) contrasts with the trailing EPS of just $0.038, illustrating how much the recent quarters have improved versus the prior year. For a capital-intensive OSAT, these margins are respectable but structurally thin compared to fabless designers, and the key question is whether the sequential margin expansion can be sustained as depreciation from heavy capex ramps.
Balance sheet health is a relative bright spot: debt-to-equity is a modest 0.35, the current ratio is a strong 2.27, and cash sits at $1.80 billion, giving Amkor substantial liquidity. However, free cash flow is a concern — TTM FCF is $532 million, but the most recent quarter (Q3 2026) posted negative free cash flow of -$61.6 million as capital expenditures of $548 million overwhelmed operating cash flow of $487 million, reflecting the aggressive capacity build-out. ROE of 8.36% and ROA of 4.86% are modest, and the negative quarterly FCF alongside a -$210.86 price-to-free-cash-flow ratio signals that the company is in a heavy investment phase where cash generation is being plowed back into capacity — a bet on future AI packaging demand that the market is currently questioning.
Quarterly Revenue
$2.0B
2026-09
Revenue YoY Growth
+0.2%
YoY Comparison
Gross Margin
18.3%
Latest Quarter
Free Cash Flow
$532361000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AMKR Overvalued?
Because Amkor is profitable (Q3 2026 net income of $190.6 million, TTM EPS positive at $0.038), the PE ratio is the appropriate primary metric, and here the picture is bifurcated: the trailing PE of 26.15x reflects the depressed trailing earnings base, while the forward PE of just 10.98x implies the market expects earnings to roughly double — a massive gap that signals either significant expected earnings recovery or deep skepticism about forward estimates. The PEG ratio of 5.38 is elevated, suggesting the market is paying a high price relative to expected growth, while the PS ratio of 1.45x and EV/Sales of 1.23x are modest for a semiconductor-adjacent business, and the EV/EBITDA of 8.56x is reasonable for a capital-intensive manufacturer.
Against the broader semiconductor industry, Amkor's multiples look cheap on most measures — a PS of 1.45x and EV/EBITDA of 8.56x are well below the premium multiples typically commanded by chip designers and even many equipment makers, reflecting the OSAT model's lower margins (13.99% gross, 5.57% net) and capital intensity. The forward PE of 10.98x versus a trailing PE of 26.15x implies the market is pricing in a dramatic earnings rebound, yet the stock's collapse suggests investors doubt that rebound will materialize on schedule. The premium-to-discount question hinges on whether Amkor's advanced packaging exposure to AI/HPC justifies a re-rating toward foundry-adjacent multiples, or whether competitive pressure from TSMC and Intel caps its pricing power and keeps it a low-multiple contract manufacturer.
Historically, Amkor's valuation has compressed dramatically: the PS ratio was 6.53x as recently as Q3 2026 reporting (per historical ratios) and 11.25x in Q2 2026, versus the current 1.45x — a collapse to the very bottom of its multi-year band. The PE ratio similarly ranged from 14x to 33x over the past two years and now sits at 26.15x trailing but 10.98x forward, while the price-to-book of 2.18x is near the lower end of its historical 1.1x-4.6x range. This places Amkor at or near historical valuation lows, which could represent a genuine value opportunity if the AI packaging thesis holds — or, more ominously, could reflect fundamental deterioration and a market that has lost confidence in the growth story, a distinction that will only be resolved by upcoming earnings delivery.
PE
26.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 3x~53x
vs. Industry Avg
54.4x
Industry PE ~54.4x*
EV/EBITDA
8.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the mismatch between heavy capital spending and flat revenue. Q3 2026 capex of $548 million exceeded operating cash flow of $487 million, producing negative free cash flow of -$61.6 million, while revenue grew only 0.18% year-over-year — meaning the capacity being built is not yet generating incremental sales. Revenue concentration is acute: advanced products generated $1.632 billion, roughly 82% of the $1.991 billion total, tying Amkor's fortunes to a single AI/HPC packaging cycle, and depreciation and amortization of $186.6 million in Q3 will climb as new capacity comes online, pressuring the 18.26% gross margin. The balance sheet is a mitigant — debt-to-equity of 0.35, current ratio of 2.27, and $1.80 billion of cash — but TTM net margin of 5.57% and ROE of 8.36% leave little cushion if volumes disappoint. Market and competitive risks are dominated by valuation compression and the foundry threat. The stock's beta of 2.402 means a 10% S&P decline could translate to a roughly 24% AMKR decline, and the 1-month relative strength of -36.97% versus SPY's -5.92% shows the de-rating is stock-specific rather than macro-driven. Competition from TSMC and Intel — both larger, foundry-backed, and capable of bundling packaging with wafer fabrication — threatens Amkor's pricing power precisely as it commits capital to advanced packaging, and the TSMC partnership that drove the June rally to $93.55 cuts both ways if it subordinates Amkor to a partner's roadmap. The PEG of 5.38 and forward PE of 10.98x versus trailing 26.15x mean the market has already priced in an earnings rebound; any delay in that rebound triggers further multiple compression. The worst-case scenario is a chain in which Q4 or Q1 revenue fails to reaccelerate, depreciation from the capex ramp compresses gross margin back toward the 14.19% Q1 level, and analysts cut the stale $66.00 average target toward the $41.00 low — a sequence that would break the $29.76 support with no historical price memory below it. From the current $30.49, a move to the 52-week low is only -2.4%, but a retest of the October consolidation breakdown and a slide toward the $25-$27 zone implied by a 9x multiple on lowered earnings would represent roughly -12% to -18%, and a full capitulation toward the analyst low of $41.00 is actually above the current price, underscoring that the downside is now defined by estimate cuts rather than published targets. Given the -67.41% max drawdown already realized, further losses are more likely to come in violent 15-20% single-session gaps like the -14.50% move on November 5 than in gradual erosion.
FAQ
The most severe risk is financial: Q3 2026 capex of $548 million exceeded operating cash flow of $487 million, producing -$61.6 million of free cash flow while revenue grew just 0.18% YoY, so the capacity build-out is not yet self-funding. Second is competitive: TSMC and Intel are larger, foundry-backed rivals capable of bundling packaging with wafer fabrication, which threatens Amkor's pricing power precisely as it commits capital to advanced packaging, and 82% of revenue ($1.632 billion of $1.991 billion) is concentrated in advanced products tied to one AI/HPC cycle. Third is valuation and volatility: beta of 2.402 and a -67.41% max drawdown mean single-session gaps of 14-15% are realistic, and the 1-month relative strength of -36.97% versus SPY's -5.92% confirms stock-specific selling. Fourth is estimate risk: the $66.00 average target looks stale against a stock that fell 42.89% in a month, and a wave of target cuts toward the $41.00 low would remove the last valuation anchor.
The 12-month forecast is split three ways. The base case carries 55% probability with a $38-$48 range, assuming revenue stabilizes in low-single-digit growth, gross margin holds between roughly 16% and 18% as depreciation climbs, and free cash flow turns modestly positive as capex normalizes from the $548 million Q3 peak. The bear case at 25% probability targets $22-$29.76, driven by a revenue miss, gross margin sliding back toward 14%, and analyst cuts below the $41.00 low that break the $29.76 support. The bull case at 20% probability targets $66-$92, requiring AI/HPC packaging volumes to ramp, the TSMC partnership to convert into named orders, and quarterly EPS to validate the 10.98x forward PE as a genuine discount. The base case is most likely because the sequential margin expansion (gross margin 14.19% to 18.26% across 2026) is real, but the top line has not yet confirmed it.
The valuation is bifurcated and depends on which earnings base you trust. Trailing PE of 26.15x looks full for a contract manufacturer with 13.99% TTM gross margin, but forward PE of 10.98x implies the market expects earnings to roughly double — a discount that only holds if the Q3 2026 EPS of $0.77 annualizes near $3.00. PS of 1.45x has collapsed from 6.53x at Q3 reporting and 11.25x in Q2 2026, and P/B of 2.18x sits near the bottom of its 1.1x-4.6x historical band, while EV/EBITDA of 8.56x is modest for a capital-intensive manufacturer. Against semiconductor peers, these multiples are cheap, but the PEG of 5.38 signals the market is not paying up for expected growth. The market is effectively pricing AMKR as a low-multiple contract manufacturer until the AI packaging revenue shows up — undervalued versus its own history and analyst targets, but fairly-to-fully valued versus currently delivered flat growth.
From a risk/reward standpoint, AMKR offers an asymmetric but unproven setup: the stock at $30.49 sits 1.1% above its $29.76 52-week low, every analyst target ($41.00 low to $92.00 high, $66.00 average) is above the price, and the forward PE of 10.98x is less than half the trailing 26.15x. The downside is equally concrete — revenue grew only 0.18% YoY in Q3 2026, free cash flow was -$61.6 million, and a beta of 2.402 means a 10% market decline could translate to roughly a 24% AMKR decline. The stock has already fallen 42.89% in a month and 60.20% in six months, so the falling knife is still in motion. It is a reasonable buy only for risk-tolerant investors who size positions small, accept a 2-3 year horizon, and wait for confirmation of positive YoY revenue growth plus positive free cash flow before adding. For conservative or income-oriented investors, the 0.84% dividend yield and 5.57% net margin offer no cushion.
AMKR is better suited to a patient, long-term holding period of at least 2-3 years than to short-term trading, despite — or because of — its volatility. The beta of 2.402 and the -14.50% single-session drop on November 5 mean short-term traders face violent gap risk in both directions, and the 2.76-day short ratio creates squeeze potential that is difficult to time. The long-term case rests on the balance sheet (debt-to-equity 0.35, current ratio 2.27, $1.80 billion cash) and the structural AI/HPC packaging opportunity, but earnings visibility is low given flat 0.18% YoY revenue and negative quarterly free cash flow, so position sizing should be small. The 0.84% dividend yield with a 21.9% payout ratio provides token income but no meaningful total-return support. A reasonable approach is a staged entry over several quarters, adding only on confirmation of positive YoY revenue growth and positive free cash flow, with a hard review if the stock breaks decisively below $29.76.